COM902 / Compugen, Xoma - LARVOL DELTA

Triple blockade of DNAM-1axis with COM701(anti-PVRIG)+COM902(anti-TIGIT)+Pembrolizumab shows prelim antitumor activity in pts with platinum resistant ovarian cancer, interim results of phase I trial (SITC 2024) - P1 | "A 20% objective response rate (ORR) following combination COM701 + BMS-986207 (anti-TIGIT) + nivolumab in PROC was previously reported.3 We present an additional cohort of PROC pts treated with COM701, COM902 and pembrolizumab demonstrating encouraging antitumor activity, and safety, consistent with the prior report.4 Methods CPG-02-101 is ongoing...One PR pt had prior treatment with mirvetuximab soravtansine-gynx...Ethics Approval The CPG-02-101 trial is being conducted in accordance with the ethical principles stipulated in the Declaration of Helsinki. View this table:View inline View popup Download powerpoint Abstract 985 Table 1 Subject dispositionView this table:View inline View popup Download powerpoint Abstract 985 Table 2 Summary of overall response rate (ORR) and disease control rate (DCR)View this table:View inline View popup Download powerpoint Abstract 985 Table 3 Overall Summary of TEAEs ovarian cancer, triplet dose expansionView this table:View inline..."

Clinical • P1 data • Oncology • Ovarian Cancer • Solid Tumor • IFNG • TIGIT

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PRNewswire) - "Compugen Ltd...announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer. U.S. Patent No. 12152084 titled 'Triple combination antibody therapies' augments patents previously issued to Compugen by expanding and protecting the use of COM902 and backup antibodies for treating cancer patients, to include the triplet combination of COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody....U.S. Patent No. 12152084 is expected to expire no earlier than August 2037 in the United States."

Patent • Oncology

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PRNewswire) - P1 | N=110 | NCT04354246 | Sponsor: Compugen Ltd | "Compugen Ltd...announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC)....'The data from this study along with data Compugen previously presented, demonstrate that COM701 is active, has a favorable safety profile, and is a differentiated immune checkpoint inhibitor. COM701 in combination with COM902 (Fc reduced anti-TIGIT) and pembrolizumab (anti-PD-1) resulted in durable objective responses in late-stage ovarian cancer patients typically not responsive to other immunotherapeutic agents'."

P1 data • Ovarian Cancer

Compugen to Present New Clinical Data at SITC 2024 (PRNewswire) - "Compugen Ltd...today announced, that new clinical data supporting the anti-tumor activity and safety of the triple combination COM701, COM902 and pembrolizumb in heavily pre-treated patients with platinum resistant ovarian cancer will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024, in Houston, Texas."

P1 data • Gynecologic Cancers • Oncology • Ovarian Cancer

Compugen Reports Second Quarter 2024 Results (PRNewswire) - "Upcoming Expected Milestones - COM701 +COM902 + pembrolizumab proof-of-concept study: Platinum resistant ovarian cancer - data presentation in the fourth quarter of 2024. COM503 (licensed to Gilead; Compugen leads through Phase 1 development): Initiation of COM503 Phase 1 trial in the fourth quarter of 2024. Rilvegostomig (AstraZeneca's PD-1/TIGIT bispecific, TIGIT component derived from COM902): AstraZeneca anticipates data from Phase 1/2 ARTEMIDE-01 trial in the second half of 2024; poster presentation from Phase 2 GEMINI-Gastric trial accepted at ESMO 2024."

New P1 trial • P1 data • P1/2 data • P2 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases. (ASCO 2024) - P1 | "Key inclusion criteria: Age ≥ 18 yrs, measurable disease, MSS by IHC or genomic testing, ≤3 prior lines including fluroropyrimidines, irinotecan, and oxaliplatin. The data further supports the antitumor activity of the combination of COM701 + COM902 + pembrolizumab in pts with MSS-CRC and specifically in patients with liver metastases. Of note the data further reinforces the data previously disclosed in a similar pt population of 22 pts that received COM701 + nivolumab 1 . No new safety signals are reported."

Clinical • Combination therapy • Colorectal Cancer • Fatigue • Immune Modulation • Immunology • Musculoskeletal Pain • Oncology • Pain • PD-1 • TIGIT

Compugen Reports First Quarter 2024 Results (PRNewswire) - "Upcoming Expected Milestones - COM701 +COM902 + pembrolizumab proof-of-concept studies: Microsatellite stable colorectal cancer – ASCO poster presentation, June 1, 2024; Platinum resistant ovarian cancer - planned data presentation in the fourth quarter of 2024....Rilvegostomig (AstraZeneca's PD-1/TIGIT bispecific, TIGIT component derived from COM902): Data in the second half of 2024 from Phase 1/2 ARTEMIDE-01 trial in advanced/metastatic NSCLC."

P1 data • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 (PRNewswire) - "Compugen...today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois."

Clinical data • Colorectal Cancer

Compugen Reports Fourth Quarter and Full Year 2023 Results (PRNewswire) - "COM701 +COM902 + pembrolizumab proof-of-concept studies: Microsatellite stable colorectal cancer - data in the first half of 2024; Platinum resistant ovarian cancer - on track to complete enrolment of at least 20 patients in the first quarter of 2024, and data in the fourth quarter of 2024."

Enrollment status • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Compugen Ltd | Trial completion date: Jun 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Plasmacytoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Compugen Reports Second Quarter 2023 Results (PRNewswire) - "Next Planned Milestones in H2 2023: Report initial findings from ongoing triple combination (COM701 + COM902 + pembrolizumab) proof-of-concept studies in microsatellite stable colorectal and platinum resistant ovarian cancer by end of the year. Presentation of new translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab ± BMS anti-TIGIT. Presentation of longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 + nivolumab + BMS anti-TIGIT."

P1 data • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study (PRNewswire) - "Compugen Ltd...today announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer....This proof-of-concept study...is an open label study evaluating the combination of COM701 with COM902 and pembrolizumab in up to 40 patients with high grade platinum resistant epithelial ovarian cancer including patients with fallopian tube cancer and primary peritoneal cancer who have received up to 3 lines of prior therapy for platinum resistant ovarian cancer. The study includes patients with all histologies."

Trial status • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Peritoneal Cancer • Plasmacytoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Compugen Ltd | Trial completion date: Sep 2023 ➔ Jun 2024 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Metastases • Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Plasmacytoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

COM701 ± Nivolumab - preliminary results of antitumor activity from a phase 1 study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor. (ESMO-IO 2022) - P1a/1b | "Post ICI NSCLC data - 1 prior line of ICI in metastatic setting, mOS 14.5 mos for ramucirumab + pembrolizumab1...A P1 study in post IO NSCLC evaluating COM902+COM701+PD-1 inhibitor, COM902+COM701+chemotherapy is planned...J Clin Oncol. 2022 Jul 20; 40(21):2295-2306."

Clinical • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study (PRNewswire) - "Compugen Ltd...announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, in combination with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC)....'This milestone keeps us on track to report initial findings by the end of this year...'"

P1 data • Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer (PRNewswire) - "Compugen is planning to pursue two studies, with the purpose to strengthen the data it has already published and to build a path to future registration studies: The first, in up to 20 patients with metastatic MSS-CRC, immune checkpoint inhibitor naïve patients with ≤ 2L of prior therapy, treated with a triple combination of Compugen's anti-PVRIG, COM701, and its own anti-TIGIT, COM902, and pembrolizumab. Enrolment is expected to be completed in 2023. The second is a follow up study currently under design in platinum resistant ovarian cancer immune checkpoint inhibitor naïve patients....Compugen expects to share initial findings by the end of 2023."

Clinical data • New trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology

COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246). (SITC 2021) - P1 | "Enrollment into combination cohort (COM902 + COM701), for evaluation of safety/tolerability at the RDFE of both study drugs, combination dose expansion (COM902 + COM701) in pts with HNSCC, NSCLC and CRC-MSS and COM902 monotherapy dose expansion (pts with multiple myeloma) all at the RDFE of study drug(s) are planned. Data cut June 28, 2021. Trial Registration NCT04354246"

Clinical • Monotherapy • PK/PD data • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • TIGIT

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Compugen Ltd | Trial completion date: Sep 2022 ➔ Sep 2023 | Trial primary completion date: Sep 2021 ➔ Jan 2023

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Plasmacytoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma - (PRNewswire) - "Compugen Ltd...announced the presentation of new research suggesting that targeting PVRIG and TIGIT holds promise for treating multiple myeloma. The research on the expression of PVRIG and TIGIT pathway in the bone marrow of multiple myeloma patients conducted in collaboration with Dr. James Berenson and his team at the Institute for Myeloma and Bone Cancer Research, will be presented as a poster at the American Association for Cancer Research (AACR) annual meeting to take place on April 8-13, 2022, in New Orleans, Louisiana."

Clinical data • Multiple Myeloma • Oncology

COM902: "COM902 monotherapy has a favorable safety and toxicity profile and is well tolerated"; Solid tumors (Compugen) - SITC 2021: "Encouraging signal of antitumor activity with SD 9 pts (50%) and 6 pts (67%) with confirmed SD; 3 pts (17%) with SD ≥6 months [includes an additional pt with SD ≥6 months within the datacut date, data entry delayed] in a heavily pretreated and heterogenous pt population with median (min, max) 7 (2, 16) prior therapies"

P1 data • Oncology • Solid Tumor

Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021 (PRNewswire) - P1, N=90; NCT04354246; Sponsor: Compugen Ltd; COM902 administered IV Q3W was well tolerated with a favorable safety profile. A maximum tolerated dose of COM902 was not reached. One patient in the 0.01 mg/kg dose cohort reported a dose limiting toxicity (DLT) of Grade 2 vomiting, and one patient in the 1 mg/kg dose cohort had a DLT of Grade 3 atrial fibrillation; these were assessed by the investigator as possibly related to study treatment with COM902; No DLTs were reported at any other COM902 doses including higher doses (3 mg/kg, 10 mg/kg). COM902 3 mg/kg IV Q3W has been selected as the recommended dose for expansion. Best response of stable disease (SD) was reported in 9 patients (50%), with 6 patients (67%) having confirmed SD and 3 patients (17%) with SD of at least 6 months. No depletion of major lymphocyte populations expressing TIGIT (NK, CD4 and CD8 T cells) in the peripheral blood analysis."

P1 data • Oncology • Solid Tumor

Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902 (PRNewswire) - "Compugen Ltd...announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca...triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen's high-affinity clinical-stage anti-TIGIT antibody....To date, Compugen has received a $10 million upfront payment, an additional $2 million milestone payment and is entitled to an additional $6 million payment triggered by this first patient being dosed, out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales."

Commercial • Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021 (PRNewswire) - "Compugen Ltd...announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 10-14, 2021."

P1 data • P1/2 data • Preclinical • Oncology • Solid Tumor

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development (PRNewswire) - “Compugen Ltd…announced that a bispecific antibody of AstraZeneca derived from COM902, Compugen's high affinity anti-TIGIT antibody, will advance into clinical development. AstraZeneca (LSE/STO/Nasdaq: AZN) plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.”

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1; N=90; Recruiting; Sponsor: Compugen Ltd; N=45 ➔ 90

Clinical • Enrollment change • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Plasmacytoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck